IL101708A - Anti-fattening drugs comprising amino acid derivatives - Google Patents

Anti-fattening drugs comprising amino acid derivatives

Info

Publication number: IL101708A
Authority: IL; Israel
Prior art keywords: fattening; formula; drugs; group; amino acid
Prior art date: 1992-04-28

Application number

IL10170892A

Other languages

English (en)

Other versions

IL101708A0 (en

Original Assignee

Senyorina Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-04-28

Filing date

1992-04-28

Publication date

1996-08-04

1992-04-28 Application filed by Senyorina Ltd filed Critical Senyorina Ltd

1992-04-28 Priority to IL10170892A priority Critical patent/IL101708A/en

1992-12-30 Publication of IL101708A0 publication Critical patent/IL101708A0/xx

1993-04-27 Priority to JP51890793A priority patent/JP3666667B2/ja

1993-04-27 Priority to PCT/EP1993/001014 priority patent/WO1993021913A1/fr

1993-04-27 Priority to DE69309457T priority patent/DE69309457T2/de

1993-04-27 Priority to DK93909847.1T priority patent/DK0637958T3/da

1993-04-27 Priority to CA002134560A priority patent/CA2134560C/fr

1993-04-27 Priority to AU40626/93A priority patent/AU4062693A/en

1993-04-27 Priority to AT93909847T priority patent/ATE150967T1/de

1993-04-27 Priority to EP93909847A priority patent/EP0637958B1/fr

1996-03-18 Priority to US08/616,948 priority patent/US5602164A/en

1996-08-04 Publication of IL101708A publication Critical patent/IL101708A/en

Links

229940079593 drug Drugs 0.000 title description 8
239000003814 drug Substances 0.000 title description 8
150000003862 amino acid derivatives Chemical class 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 17
208000008589 Obesity Diseases 0.000 claims abstract description 7
150000001413 amino acids Chemical class 0.000 claims abstract description 7
235000020824 obesity Nutrition 0.000 claims abstract description 7
FSYKKLYZXJSNPZ-UHFFFAOYSA-N N-methylaminoacetic acid Natural products C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims description 5
239000004480 active ingredient Substances 0.000 claims description 5
239000004471 Glycine Substances 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
235000015872 dietary supplement Nutrition 0.000 claims description 3
SAUDSWFPPKSVMK-LBPRGKRZSA-N (2s)-2-(n-phenylanilino)propanoic acid Chemical compound C=1C=CC=CC=1N([C@@H](C)C(O)=O)C1=CC=CC=C1 SAUDSWFPPKSVMK-LBPRGKRZSA-N 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
102100037644 Kelch-like protein 41 Human genes 0.000 claims 2
108050003242 Kelch-like protein 41 Proteins 0.000 claims 2
NPKKRSHVJIQBKU-UHFFFAOYSA-N ornogenin Natural products CC(OC(=O)C=Cc1ccccc1)C2(O)CCC3(O)C4(O)CC=C5CC(O)CCC5(C)C4CC(OC(=O)C=Cc6ccccc6)C23C NPKKRSHVJIQBKU-UHFFFAOYSA-N 0.000 claims 2
241000699670 Mus sp. Species 0.000 description 10
150000002632 lipids Chemical class 0.000 description 9
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
235000005911 diet Nutrition 0.000 description 8
230000037213 diet Effects 0.000 description 7
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
229940024606 amino acid Drugs 0.000 description 5
210000004185 liver Anatomy 0.000 description 5
239000000203 mixture Substances 0.000 description 5
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
210000000577 adipose tissue Anatomy 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000010348 incorporation Methods 0.000 description 4
238000000034 method Methods 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
230000002265 prevention Effects 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
LFJJOPDNPVFCNZ-UHFFFAOYSA-N 2-[hexadecanoyl(methyl)amino]acetic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N(C)CC(O)=O LFJJOPDNPVFCNZ-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
235000014633 carbohydrates Nutrition 0.000 description 3
235000013305 food Nutrition 0.000 description 3
239000013589 supplement Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
HYSMCRNFENOHJH-UHFFFAOYSA-N MEDICA 16 Chemical compound OC(=O)CC(C)(C)CCCCCCCCCCC(C)(C)CC(O)=O HYSMCRNFENOHJH-UHFFFAOYSA-N 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
239000002285 corn oil Substances 0.000 description 2
235000005687 corn oil Nutrition 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
210000005228 liver tissue Anatomy 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
229940043230 sarcosine Drugs 0.000 description 2
CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
229920002527 Glycogen Polymers 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
-1 P-Sar Hydroxy succinimide ester Chemical class 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
241000700159 Rattus Species 0.000 description 1
108010077895 Sarcosine Proteins 0.000 description 1
XLYOFNOQVPJJNP-PWCQTSIFSA-N Tritiated water Chemical compound [3H]O[3H] XLYOFNOQVPJJNP-PWCQTSIFSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000012043 crude product Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
150000001991 dicarboxylic acids Chemical class 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
229940096919 glycogen Drugs 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
DCAYPVUWAIABOU-NJFSPNSNSA-N hexadecane Chemical class CCCCCCCCCCCCCCC[14CH3] DCAYPVUWAIABOU-NJFSPNSNSA-N 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
231100001252 long-term toxicity Toxicity 0.000 description 1
235000004213 low-fat Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
235000021590 normal diet Nutrition 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
238000005406 washing Methods 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL10170892A 1992-04-28 1992-04-28 Anti-fattening drugs comprising amino acid derivatives IL101708A (en)

Priority Applications (10)

Application Number	Priority Date	Filing Date	Title
IL10170892A IL101708A (en)	1992-04-28	1992-04-28	Anti-fattening drugs comprising amino acid derivatives
EP93909847A EP0637958B1 (fr)	1992-04-28	1993-04-27	Medicaments contre l'obesite
DK93909847.1T DK0637958T3 (da)	1992-04-28	1993-04-27	Anti-fedme medikamenter
PCT/EP1993/001014 WO1993021913A1 (fr)	1992-04-28	1993-04-27	Medicaments contre l'obesite
DE69309457T DE69309457T2 (de)	1992-04-28	1993-04-27	Wirkstoffe gegen fettleibigkeit
JP51890793A JP3666667B2 (ja)	1992-04-28	1993-04-27	抗−肥満薬
CA002134560A CA2134560C (fr)	1992-04-28	1993-04-27	Medicaments contre l'obesite
AU40626/93A AU4062693A (en)	1992-04-28	1993-04-27	Anti-obesity drugs
AT93909847T ATE150967T1 (de)	1992-04-28	1993-04-27	Wirkstoffe gegen fettleibigkeit
US08/616,948 US5602164A (en)	1992-04-28	1996-03-18	Anti-obesity drugs

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IL10170892A IL101708A (en)	1992-04-28	1992-04-28	Anti-fattening drugs comprising amino acid derivatives

Publications (2)

Publication Number	Publication Date
IL101708A0 IL101708A0 (en)	1992-12-30
IL101708A true IL101708A (en)	1996-08-04

Family

ID=11063576

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL10170892A IL101708A (en)	1992-04-28	1992-04-28	Anti-fattening drugs comprising amino acid derivatives

Country Status (9)

Country	Link
EP (1)	EP0637958B1 (fr)
JP (1)	JP3666667B2 (fr)
AT (1)	ATE150967T1 (fr)
AU (1)	AU4062693A (fr)
CA (1)	CA2134560C (fr)
DE (1)	DE69309457T2 (fr)
DK (1)	DK0637958T3 (fr)
IL (1)	IL101708A (fr)
WO (1)	WO1993021913A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1271267B (it) *	1994-12-14	1997-05-27	Valle Francesco Della	Ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
ATE318591T1 (de) *	2001-11-26	2006-03-15	Lean Ex Ltd	Pharmazeutische zusammensetzung zur behandlung von fettleibigkeit
EP1550670A4 (fr) *	2002-10-07	2007-06-13	Nat Inst Of Advanced Ind Scien	Particules spheriques fines possedant une orientation moleculaire satisfaisante, microcapsules spheriques les contenant et procedes de production
ITMI20041567A1 (it) *	2004-07-30	2004-10-30	Maycos Italiana Di Comini Miro	"derivati n-acilati di acidi bicarbossilici con amminoacidi e con idrolizzati proteici vegetali e loro applicazione in prodotti cosmetici, dermofarmaceutici e farmaceutici"
WO2007013062A1 (fr) *	2005-07-25	2007-02-01	Lean-Ex Ltd.	Composition et procede de stabilisation du poids
CN104649926B (zh) *	2013-11-25	2018-08-17	刘现梅	一种n,n’-癸二酰基二天门冬氨酸及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2234399A1 (de) *	1972-07-17	1974-01-31	Thomae Gmbh Dr K	Hautschutzmittel
DE3423166A1 (de) *	1984-06-22	1986-01-02	Epis S.A., Zug	Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten

1992
- 1992-04-28 IL IL10170892A patent/IL101708A/en active IP Right Grant
1993
- 1993-04-27 JP JP51890793A patent/JP3666667B2/ja not_active Expired - Fee Related
- 1993-04-27 AT AT93909847T patent/ATE150967T1/de not_active IP Right Cessation
- 1993-04-27 EP EP93909847A patent/EP0637958B1/fr not_active Expired - Lifetime
- 1993-04-27 AU AU40626/93A patent/AU4062693A/en not_active Abandoned
- 1993-04-27 WO PCT/EP1993/001014 patent/WO1993021913A1/fr not_active Ceased
- 1993-04-27 CA CA002134560A patent/CA2134560C/fr not_active Expired - Fee Related
- 1993-04-27 DK DK93909847.1T patent/DK0637958T3/da active
- 1993-04-27 DE DE69309457T patent/DE69309457T2/de not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DK0637958T3 (da)	1997-10-13
EP0637958B1 (fr)	1997-04-02
WO1993021913A1 (fr)	1993-11-11
CA2134560C (fr)	2002-03-19
DE69309457T2 (de)	1997-11-06
CA2134560A1 (fr)	1993-11-11
ATE150967T1 (de)	1997-04-15
JPH07508719A (ja)	1995-09-28
IL101708A0 (en)	1992-12-30
EP0637958A1 (fr)	1995-02-15
DE69309457D1 (de)	1997-05-07
AU4062693A (en)	1993-11-29
JP3666667B2 (ja)	2005-06-29

Legal Events

Date	Code	Title
1997-01-10	FF	Patent granted
1997-03-18	KB	Patent renewed
1998-11-26	HP	Change in proprietorship
1998-11-26	KB	Patent renewed
2002-06-30	KB	Patent renewed
2006-10-04	KB	Patent renewed

Publication	Publication Date	Title
EP1014965B1 (fr)	2004-01-14	Compositions dietetiques servant a ameliorer le metabolisme et attenuer les agressions oxydatives
AU664511B2 (en)	1995-11-16	Method of promoting nitrogen retention in humans
US4499076A (en)	1985-02-12	Elemental diets for liver diseases
US4268524A (en)	1981-05-19	Method of treating abnormal lipoprotein ratios with acylcarnitine
ITRM950824A1 (it)	1997-06-15	Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi
JP2009242413A (ja)	2009-10-22	アミノ酸をベースとする医薬
Hänni	1978	Pharmacokinetic and metabolic pathways of systemically applied retinoids
US5420335A (en)	1995-05-30	Parenteral nutrients based on watersoluble glycerol bisacetoacetates
WO2008069652A1 (fr)	2008-06-12	Combinaisons d'un sphingolipide et d'un inhibiteur de la hmg-coa réductase pour le traitement de l'hypercholestérolémie
EP0637958B1 (fr)	1997-04-02	Medicaments contre l'obesite
AU679818B2 (en)	1997-07-10	Butyric ester cyto-differentiating agents
US5602164A (en)	1997-02-11	Anti-obesity drugs
US4997852A (en)	1991-03-05	Method and composition for achieving cancer chemopreventive and chemotherapeutic activity
EP0501641A1 (fr)	1992-09-02	L-2-oxothiazolidine-4-carboxylate et esters du glutathion pour le traitement des maladies hépatiques
EP0363337A1 (fr)	1990-04-11	Substrat d'énergie contenant un acide hydroxycarboxylique
AU2007358961A1 (en)	2009-03-19	Composition and method for increasing the anabolic state of muscle cells
US7645794B2 (en)	2010-01-12	Composition and method for increasing the anabolic state of muscle cells
US20130296390A1 (en)	2013-11-07	Method and compositions for enhancing the safety of orally administered magnesium alpha-lipoate
CA2598786C (fr)	2012-01-03	Composition et procede d'augmentation de l'anabolisme des cellules musculaires
US20050250674A1 (en)	2005-11-10	Nutritional and food supplement preparation comprising creatine and orotic acid complexes, derivatives and analogs
ITRM980445A1 (it)	2000-01-03	Composizioni solide atte alla somministrazione orale comprendenti sali non igroscopici della l-carnitina e delle alcanoil l-carnitine
EP0003353A1 (fr)	1979-08-08	Composition pharmaceutique pour administration par voie orale pour le traitement de l'hypertension
JPWO2002074299A1 (ja)	2004-07-08	ＴＮＦα産生抑制剤
JPH07206684A (ja)	1995-08-08	肝障害抑制剤